Trastuzumab in Addition to Chemotherapy in Patients With Metastatic Human Epidermal Growth Factor Receptor 2–Positive Gastroesophageal Cancer—A Real-World Experience
Clinical Oncology · 2026-07 · 55 · 104169
DOI: 10.1016/j.clon.2026.104169 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Oncology, 2026-07. Verfasst von M Korpan und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine I, Division of Oncology, Medical University of Vienna, Waehringer Guertel 18-20, A1090, Vienna, Austria; Christian Doppler Lab…. Hauptthemen laut MEDLINE: Trastuzumab, Esophageal Neoplasms, Stomach Neoplasms, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bundesministerium für Digitalisierung und Wirtschaftsstandort, Österreichische Nationalstiftung für Forschung, Technologie und Entwicklung, Christian Doppler Forschungsgesellschaft.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine I, Division of Oncology, Medical University of Vienna, Waehringer Guertel 18-20, A1090, Vienna, Austria; Christian Doppler Laboratory for Personalized Immunotherapy, Medical University of Vienna,…
- Department of Medicine I, Division of Oncology, Medical University of Vienna, Waehringer Guertel 18-20, A1090, Vienna, Austria. Electronic address: n11935602@students.meduniwien.ac.at.
- Department of Medicine I, Division of Oncology, Medical University of Vienna, Waehringer Guertel 18-20, A1090, Vienna, Austria. Electronic address: n11910038@students.meduniwien.ac.at.
- Department of Medicine I, Division of Oncology, Medical University of Vienna, Waehringer Guertel 18-20, A1090, Vienna, Austria. Electronic address: n11917161@students.meduniwien.ac.at.
- Department of Medicine I, Division of Oncology, Medical University of Vienna, Waehringer Guertel 18-20, A1090, Vienna, Austria. Electronic address: n11943895@students.meduniwien.ac.at.
- Department of Medicine I, Division of Oncology, Medical University of Vienna, Waehringer Guertel 18-20, A1090, Vienna, Austria. Electronic address: n12007277@students.meduniwien.ac.at.
Förderung
- Bundesministerium für Digitalisierung und Wirtschaftsstandort
- Österreichische Nationalstiftung für Forschung, Technologie und Entwicklung
- Christian Doppler Forschungsgesellschaft
Zitieren
APA
Korpan, M., Simonis, L., Soellner, V., Edelson, R. S., Becker, L. J., Pellizzari, M., Karimi, J. V., Berger, J. M., Prager, G. W., Bergen, E. S., Berghoff, A. S., Preusser, M., Ilhan-Mutlu, A., & Puhr, H. C. (2026). Trastuzumab in Addition to Chemotherapy in Patients With Metastatic Human Epidermal Growth Factor Receptor 2–Positive Gastroesophageal Cancer—A Real-World Experience. Clinical Oncology, 55, 104169. https://doi.org/10.1016/j.clon.2026.104169
Vancouver
Korpan M, Simonis L, Soellner V, Edelson RS, Becker LJ, Pellizzari M, et al. Trastuzumab in Addition to Chemotherapy in Patients With Metastatic Human Epidermal Growth Factor Receptor 2–Positive Gastroesophageal Cancer—A Real-World Experience. Clinical Oncology. 2026;55:104169. doi:10.1016/j.clon.2026.104169
BibTeX
@article{Korpan2026,
author = {Korpan, M and Simonis, L and Soellner, V and Edelson, R S and Becker, L J and Pellizzari, M and Karimi, J V and Berger, J M and Prager, G W and Bergen, E S and Berghoff, A S and Preusser, M and Ilhan-Mutlu, A and Puhr, H C},
title = {Trastuzumab in Addition to Chemotherapy in Patients With Metastatic Human Epidermal Growth Factor Receptor 2–Positive Gastroesophageal Cancer—A Real-World Experience},
journal = {Clinical Oncology},
year = {2026},
volume = {55},
pages = {104169},
doi = {10.1016/j.clon.2026.104169}
}
EUVIMED